Vetr upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a strong sell rating to a sell rating in a report published on Monday. They currently have $25.50 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on JUNO. Morgan Stanley boosted their price objective on shares of Juno Therapeutics from $26.00 to $27.00 and gave the stock an equal weight rating in a research note on Monday, August 7th. Zacks Investment Research lowered shares of Juno Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 10th. Wedbush reissued a neutral rating and set a $24.00 price objective on shares of Juno Therapeutics in a research note on Tuesday, June 6th. BidaskClub lowered shares of Juno Therapeutics from a buy rating to a hold rating in a research note on Saturday, June 10th. Finally, BTIG Research lowered shares of Juno Therapeutics from a neutral rating to a sell rating and boosted their price objective for the stock from $12.00 to $23.00 in a research note on Tuesday, June 6th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $30.63.

Juno Therapeutics (NASDAQ:JUNO) opened at 27.06 on Monday. The firm’s market capitalization is $2.84 billion. The company’s 50-day moving average price is $28.84 and its 200 day moving average price is $24.82. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $34.35.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The business had revenue of $21.30 million for the quarter, compared to the consensus estimate of $15.59 million. During the same period in the previous year, the firm earned ($0.64) EPS. The company’s revenue was down 22.8% on a year-over-year basis. Equities analysts predict that Juno Therapeutics will post ($3.13) earnings per share for the current fiscal year.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/18/juno-therapeutics-inc-juno-upgraded-by-vetr-inc-to-sell.html.

In other news, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total transaction of $262,500.00. Following the completion of the transaction, the chief financial officer now directly owns 736,189 shares of the company’s stock, valued at $22,085,670. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders have sold 8,053,500 shares of company stock valued at $217,594,440 over the last three months. 15.26% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its stake in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares in the last quarter. Pacad Investment Ltd. acquired a new stake in shares of Juno Therapeutics during the second quarter worth approximately $105,000. QS Investors LLC acquired a new stake in shares of Juno Therapeutics during the second quarter worth approximately $135,000. Great West Life Assurance Co. Can boosted its stake in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares in the last quarter. Finally, Nisa Investment Advisors LLC acquired a new stake in shares of Juno Therapeutics during the first quarter worth approximately $200,000. 65.03% of the stock is owned by institutional investors and hedge funds.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.